Melanoma vaccine - Epimmune

Drug Profile

Melanoma vaccine - Epimmune

Alternative Names: CY 2010; Theradigm - MAGE3

Latest Information Update: 16 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Epimmune
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 07 Jan 2000 A phase I study has been added to the adverse events section and the Cancer therapeutic trials section
  • 31 Dec 1997 Discontinued - Phase-II for Malignant melanoma in USA (unspecified route)
  • 25 Aug 1997 Phase-II clinical trials for Malignant melanoma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top